| __timestamp | CRISPR Therapeutics AG | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 46425000 |
| Thursday, January 1, 2015 | 12573000 | 81491000 |
| Friday, January 1, 2016 | 42238000 | 94291000 |
| Sunday, January 1, 2017 | 69800000 | 121827000 |
| Monday, January 1, 2018 | 113773000 | 160524000 |
| Tuesday, January 1, 2019 | 179362000 | 200000000 |
| Wednesday, January 1, 2020 | 266946000 | 275000000 |
| Friday, January 1, 2021 | 438633000 | 328100000 |
| Saturday, January 1, 2022 | 461645000 | 463800000 |
| Sunday, January 1, 2023 | 387332000 | 565000000 |
| Monday, January 1, 2024 | 320653000 | 731100000 |
Igniting the spark of knowledge
In the rapidly evolving biotech sector, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG have demonstrated significant growth in their R&D investments. From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking in 2023 with a 22% rise from the previous year. Meanwhile, CRISPR Therapeutics AG saw a staggering 25,500% increase in R&D spending over the same period, highlighting its aggressive pursuit of cutting-edge genetic therapies. Notably, both companies showed a consistent upward trend, with CRISPR Therapeutics AG's R&D expenses surpassing Neurocrine's in 2021. This data underscores the dynamic nature of biotech innovation, where strategic R&D investments are pivotal in driving breakthroughs and maintaining competitive advantage.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
R&D Insights: How Amgen Inc. and CRISPR Therapeutics AG Allocate Funds
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
GSK plc or CRISPR Therapeutics AG: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development Investment: Bio-Techne Corporation vs CRISPR Therapeutics AG
R&D Spending Showdown: Corcept Therapeutics Incorporated vs CRISPR Therapeutics AG